Literature DB >> 17616113

Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.

Roland Stragies1, Frank Osterkamp, Gunther Zischinsky, Doerte Vossmeyer, Holger Kalkhof, Ulf Reimer, Grit Zahn.   

Abstract

Starting from the structure of integrin alphavbeta3 in a complex with a peptidic ligand plus SAR data on nonpeptidic ligands, we derived a new class of integrin alpha5beta1 antagonists (1). Several synthesis strategies were applied to evaluate the chemical space around the essential pharmacophore groups R1 to R3 to obtain highly active and selective pyrrolidine derivatives as integrin alpha5beta1 antagonists. Integrin selectivity was controlled by switching from a sulfonamide moiety to a mesitylene amide moiety for R3. This finding represents a general feature for modulating selectivity toward other related integrin receptors. On the basis of the encouraging results from various in vitro studies, the most active compounds were selected for further in vivo studies in animal models and preclinical development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616113     DOI: 10.1021/jm070002v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

2.  Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.

Authors:  Aparna Sundaram; Chun Chen; Nilgun Isik Reed; Sean Liu; Seul Ki Yeon; Joel McIntosh; You-Zhi Tang; Hyunjun Yang; Marc Adler; Richard Beresis; Ian B Seiple; Dean Sheppard; William F DeGrado; Hyunil Jo
Journal:  Bioorg Med Chem Lett       Date:  2020-09-29       Impact factor: 2.823

3.  Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation.

Authors:  Tina Dietrich; Felix Bock; Don Yuen; Deniz Hos; Björn O Bachmann; Grit Zahn; Stanley Wiegand; Lu Chen; Claus Cursiefen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

4.  Integrin alpha5beta1 mediates attachment, migration, and proliferation in human retinal pigment epithelium: relevance for proliferative retinal disease.

Authors:  Rong Li; Arvydas Maminishkis; Grit Zahn; Doerte Vossmeyer; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

5.  MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Authors:  Jon S Zawistowski; Kazuhiro Nakamura; Joel S Parker; Deborah A Granger; Brian T Golitz; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

6.  alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation.

Authors:  Tatsuma Okazaki; Amy Ni; Oluwasheyi A Ayeni; Peter Baluk; Li-Chin Yao; Doerte Vossmeyer; Gunther Zischinsky; Grit Zahn; Jochen Knolle; Claudia Christner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

7.  Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.

Authors:  Rajib K Goswami; Yuan Liu; Cheng Liu; Richard A Lerner; Subhash C Sinha
Journal:  Mol Pharm       Date:  2012-11-14       Impact factor: 4.939

8.  Mapping the ligand-binding pocket of integrin alpha5beta1 using a gain-of-function approach.

Authors:  A Paul Mould; Ewa J Koper; Adam Byron; Grit Zahn; Martin J Humphries
Journal:  Biochem J       Date:  2009-11-11       Impact factor: 3.857

9.  Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.

Authors:  Florence Schaffner; Anne Marie Ray; Monique Dontenwill
Journal:  Cancers (Basel)       Date:  2013-01-15       Impact factor: 6.639

10.  Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.

Authors:  Rachel Barrow-McGee; Naoki Kishi; Carine Joffre; Ludovic Ménard; Alexia Hervieu; Bakhouche A Bakhouche; Alejandro J Noval; Anja Mai; Camilo Guzmán; Luisa Robbez-Masson; Xavier Iturrioz; James Hulit; Caroline H Brennan; Ian R Hart; Peter J Parker; Johanna Ivaska; Stéphanie Kermorgant
Journal:  Nat Commun       Date:  2016-06-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.